Work

Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model

Year: 2019

Type: article

Abstract: Staphylococcus aureus is the most common non-gonococcal aetiology of septic arthritis. The efficacy of iclaprim against S. aureus LS-1, a clinical strain identified from a patient with septic arthritis, was studied in MF1 mice to evaluate the activity of iclaprim, which is in clinical development, in preventing joint infections. Iclaprim (2.5–80 mg kg− 1) administered as a single dose via the tail vein reduced the incidence of S. aureus septic arthritis and mortality in an experimental murine model of septic arthritis.

Source: Access Microbiology

DOI: 10.1099/acmi.0.000052

Authors: D. B. Huang, S. Noviello, C. G. Gemmell

Institutions: Motif BioSciences (United States), Rutgers New Jersey Medical School, University of Glasgow

Language: English

Topic: Orthopedic Infections and Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $858